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Background
Single-agent Cetuximab has been shown to improve
objective response rate (ORR), progression-free survival
(PFS) and overall survival (OS) in patients (pts) with
epidermal growth factor receptor (EGFR) expressing,
KRAS wild-type (WT) metastatic colorectal cancer
(mCRC) who failed Oxaliplatin- and Irinotecan-based
therapy or are intolerant to Irinotecan. The mechanism
of action of Cetuximab is thought to rely on competitive
blockade of endogenous ligand binding and downstream
signaling, internalization and down regulation of EGFR,
as well as antibody-dependent cellular cytotoxicity
(ADCC) (Erbitux SmPC).
Imprime PGG (Imprime) is a novel immune modulator
(complex carbohydrate biologic), which harnesses innate
immune cells to enhance killing of antibody-targeted
tumor cells. In a Phase II single-arm clinical trial in
mCRC, the combination of Imprime with Cetuximab
resulted in 24% ORR, 62% disease control rate (DCR), and
median time to progression (TTP) of 12 wks (Tamayo
ME, Ann Onc 2010), representing approximate 100%
increases vs historical control (Cunningham, NEJM 2004).
ORR was 45%, DCR 82% and TTP 24 wks in pts with
KRAS WT tumors (post hoc analysis). The current trial,
sponsored by Biothera and registered with ClinicalTrials.
gov NCT01309126, EudraCT 2010-023562-51, is to con-
firm these findings in Phase III.
Trial design
Eligible pts have measurable disease, an ECOG perfor-
mance status of 0 or 1 and received prior Oxaliplatin- and
Irinotecan-based therapy or are intolerant to Irinotecan.
Approximately 795 pts will be randomized 2:1 (stratified
by geographic region, prior chemotherapy and site) to
receive weekly open-label Imprime plus Cetuximab or
Cetuximab alone until disease progression. The primary
endpoint of the study is OS; secondary endpoints include
PFS, ORR (based on RECIST 1.1), quality of life, safety
and pharmacokinetics. Exploratory endpoints include bio-
marker analyses. The primary analysis will occur when
~709 deaths have occurred. Pt screening and enrollment is
underway in the United States and Europe.
Trial Registration: ClinicalTrials.gov Identifier
NCT01309126.
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